Grifols, S.A Total Current Liabilities 2012-2025 | GRFS

Grifols, S.A total current liabilities for the quarter ending March 31, 2025 were $2.286B, a 29.71% increase year-over-year.

  • Grifols, S.A total current liabilities for 2024 were $2.333B, a 6.9% decline from 2023.
  • Grifols, S.A total current liabilities for 2023 were $2.506B, a 21.62% increase from 2022.
  • Grifols, S.A total current liabilities for 2022 were $2.061B, a 49.87% decline from 2021.

Grifols, S.A Total Current Liabilities 2012-2025 | GRFS

  • Grifols, S.A total current liabilities for 2024 were $2.333B, a 6.9% decline from 2023.
  • Grifols, S.A total current liabilities for 2023 were $2.506B, a 21.62% increase from 2022.
  • Grifols, S.A total current liabilities for 2022 were $2.061B, a 49.87% decline from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$76.3B
Zoetis (ZTS)$66.2B
Takeda Pharmaceutical (TAK)$45.9B
Daiichi Sankyo, - (DSNKY)$45.5B
BeOne Medicines - (ONC)$32.3B
Sandoz Group AG (SDZNY)$25B
Summit Therapeutics (SMMT)$19.5B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.2B
Neurocrine Biosciences (NBIX)$13.1B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.5B
Stevanato Group S.p.A (STVN)$7.5B
Corcept Therapeutics (CORT)$7.5B
Madrigal Pharmaceuticals (MDGL)$7.4B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
NewAmsterdam Pharma (NAMS)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B
Endo (NDOI)$1.6B